Ilan Zipkin

Company: Supercede Therapeutics

Job title: Chief Executive Officer

Bio:

Ilan Zipkin, Ph.D., is the Founder and CEO of Supercede Therapeutics, Inc., which is developing an oral ACTRII inhibitor to treat obesity. Ilan has been a biotechnology investor and entrepreneur for the past 25 years, including roles with MPM Capital, Prospect Venture Partners, Takeda Ventures, and most recently Aditum Bio. At Aditum, Ilan was responsible for the in-licensing of four clinical stage and five preclinical stage assets from global large Pharma and biotechnology companies, including the anti-ACTRII antibody bimagrumab from Novartis to start the company Versanis Bio, which was later acquired by Eli Lilly. While with Prospect Venture Partners, Ilan also served as CEO of Chimeros, Inc., a Prospect portfolio company developing an siRNA delivery system and multivalent biologic therapeutics. Outside of his company building activities, Ilan has also been VP, Business Development for the Parker Institute for Cancer Immunotherapy (PICI), a non-profit research institute focused on immuno-oncology, and Science Editor of BioCentury Publications, a biotechnology news and analysis publication.

Seminars:

Optimizing Activin Pathway Inhibition for Obesity – DIO Mouse Ffficacy as Monotherapy and in Combination with GLP-1 Agonism 3:40 pm

Oral small molecule inhibitors of the Activin receptor type II (ACTRII) reduce fat mass and liver mass/fat while preserving muscle in DIO mice This activity is accompanied by an increase in energy expenditure, maintenance of fat loss even after discontinuation of GLP-1 agonist treatment, and correlates with downstream signaling pathway activity in various tissues In…Read more

day: Day One

Optimizing Activin Pathway Inhibition For Obesity – Regulation of Adipose, Liver, & Muscle Metabolism 1:30 pm

TGFb superfamily signaling through the Activin receptor type II (ACTRII) selectively regulates metabolism in multiple tissues, including adipose and muscle In both DIO mice and human patients, ACTRII inhibition reduces fat mass while supporting preservation or growth of muscle mass Oral small molecule inhibitors of ACTRII have distinct effects from biologic inhibitors, likely driven by…Read more

day: Pre-Conference Day